-
Phase 3
-
-
12-17Age Range
-
48Locations
-
Recruiting
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
You're about to leave bmsclinicaltrials.com
This link takes you to a website of Bristol Myers Squibb that may have a different purpose, may have different terms and conditions, and is being provided solely to enable you to contact Bristol Myers Squibb.
You're about to leave bmsclinicaltrials.com
This link takes you to a website of Bristol Myers Squibb that may have a different purpose, may have different terms and conditions, and is being provided solely to enable you to contact Bristol Myers Squibb.
You are about to leave bmsclinicaltrials.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsclinicaltrials.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsclinicaltrials.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsclinicaltrials.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsclinicaltrials.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
Recruiting
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Experimental: Mavacamten
Experimental: Placebo